SCHEMBL15788367

SCHEMBL15788367

CCOC(=O)c1cc2c(C)c(C)n(C)c(=O)c2n1C

nearest known ligand 0.42

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.42
KMT2A Q03164 4/20 0.41
ALDH1A1 P00352 6/20 0.41
KDM4E B2RXH2 4/20 0.41
HSD17B10 Q99714 2/20 0.41
GAA P10253 2/20 0.41
HPGD P15428 1/20 0.41
RXFP1 Q9HBX9 1/20 0.40
TSHR P16473 2/20 0.40
USP2 O75604 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.37
BAZ2B Q9UIF8 1/20 0.37
BAZ2A Q9UIF9 1/20 0.37
MAPT P10636 2/20 0.36
PKM P14618 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17879719 0.80 BRD4 (0.44) MAPK1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL15788370 0.78 ALDH1A1 (0.48) KMT2AALDH1A1KDM4EGAAHPGD
SCHEMBL6803759 0.75 ESR1 (0.49) MAPK1ALDH1A1KDM4EGAASMN1; SMN2
SCHEMBL17517333 0.73 ALDH1A1 (0.41) MAPK1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL15788368 0.73 KMT2A (0.38) MAPK1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL13295979 0.73 ALDH1A1 (0.46) KMT2AALDH1A1KDM4EHSD17B10GAA
SCHEMBL7873755 0.72 ESR1 (0.44) MAPK1ALDH1A1KDM4EGAAHPGD
SCHEMBL17879720 0.71 BRD4 (0.56) MAPK1KMT2AALDH1A1KDM4EHSD17B10
SCHEMBL7881193 0.70 KMT2A (0.54) KMT2AALDH1A1KDM4EGAAHPGD
SCHEMBL27389398 0.70 ESR1 (0.45) MAPK1ALDH1A1KDM4EGAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158039-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2023-05-25 US disclosed
US-20160143916-A1 BROMODOMAIN INHIBITORS ABBVIE INC (US) 2016-05-26 US disclosed
US-9296741-B2 Bromodomain inhibitors ABBVIE INC. (US) 2016-03-29 US disclosed
US-20140162971-A1 BROMODOMAIN INHIBITORS ABBVIE INC. 2014-06-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140162971-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 MAPK1 343/4885KMT2A 405/4885ALDH1A1 1794/4885
US-20230158039-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 MAPK1 343/4885KMT2A 405/4885ALDH1A1 1794/4885
US-20160143916-A1 BROMODOMAIN INHIBITORS BRD4, BRD1, BRD3 MAPK1 343/4885KMT2A 405/4885ALDH1A1 1794/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.